Logo image of ADVM

ADVERUM BIOTECHNOLOGIES INC (ADVM) Stock Fundamental Analysis

NASDAQ:ADVM - Nasdaq - US00773U2078 - Common Stock - Currency: USD

2.93  -0.05 (-1.68%)

Fundamental Rating

3

Overall ADVM gets a fundamental rating of 3 out of 10. We evaluated ADVM against 568 industry peers in the Biotechnology industry. ADVM scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ADVM is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ADVM had negative earnings in the past year.
In the past year ADVM has reported a negative cash flow from operations.
ADVM had negative earnings in each of the past 5 years.
In the past 5 years ADVM always reported negative operating cash flow.
ADVM Yearly Net Income VS EBIT VS OCF VS FCFADVM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M

1.2 Ratios

ADVM has a Return On Assets (-40.15%) which is in line with its industry peers.
ADVM has a Return On Equity of -65.30%. This is comparable to the rest of the industry: ADVM outperforms 58.80% of its industry peers.
Industry RankSector Rank
ROA -40.15%
ROE -65.3%
ROIC N/A
ROA(3y)-50.31%
ROA(5y)-40.85%
ROE(3y)-90.51%
ROE(5y)-67.09%
ROIC(3y)N/A
ROIC(5y)N/A
ADVM Yearly ROA, ROE, ROICADVM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100

1.3 Margins

ADVM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADVM Yearly Profit, Operating, Gross MarginsADVM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5K -10K -15K -20K -25K

More info and screens

6

2. Health

2.1 Basic Checks

ADVM does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for ADVM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ADVM Yearly Shares OutstandingADVM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
ADVM Yearly Total Debt VS Total AssetsADVM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

ADVM has an Altman-Z score of -6.27. This is a bad value and indicates that ADVM is not financially healthy and even has some risk of bankruptcy.
ADVM has a Altman-Z score of -6.27. This is in the lower half of the industry: ADVM underperforms 64.96% of its industry peers.
There is no outstanding debt for ADVM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.27
ROIC/WACCN/A
WACC10.33%
ADVM Yearly LT Debt VS Equity VS FCFADVM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M 400M

2.3 Liquidity

ADVM has a Current Ratio of 5.82. This indicates that ADVM is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 5.82, ADVM is doing good in the industry, outperforming 62.50% of the companies in the same industry.
A Quick Ratio of 5.82 indicates that ADVM has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 5.82, ADVM is in the better half of the industry, outperforming 63.03% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.82
Quick Ratio 5.82
ADVM Yearly Current Assets VS Current LiabilitesADVM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 52.46% over the past year.
The Revenue for ADVM has decreased by -72.22% in the past year. This is quite bad
ADVM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.43% yearly.
EPS 1Y (TTM)52.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.61%
Revenue 1Y (TTM)-72.22%
Revenue growth 3YN/A
Revenue growth 5Y17.43%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ADVM will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.57% on average per year.
ADVM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 35.01% yearly.
EPS Next Y55.91%
EPS Next 2Y26.05%
EPS Next 3Y17.78%
EPS Next 5Y10.57%
Revenue Next Year-72.73%
Revenue Next 2Y85.56%
Revenue Next 3Y-56.54%
Revenue Next 5Y35.01%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ADVM Yearly Revenue VS EstimatesADVM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
ADVM Yearly EPS VS EstimatesADVM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ADVM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADVM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADVM Price Earnings VS Forward Price EarningsADVM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADVM Per share dataADVM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

A more expensive valuation may be justified as ADVM's earnings are expected to grow with 17.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.05%
EPS Next 3Y17.78%

More info and screens

0

5. Dividend

5.1 Amount

ADVM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADVERUM BIOTECHNOLOGIES INC

NASDAQ:ADVM (4/17/2025, 8:00:54 PM)

2.93

-0.05 (-1.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-15 2025-04-15/bmo
Earnings (Next)05-08 2025-05-08/amc
Inst Owners68.19%
Inst Owner Change0%
Ins Owners11.62%
Ins Owner Change1.61%
Market Cap61.21M
Analysts82.86
Price Target28.56 (874.74%)
Short Float %8.91%
Short Ratio8.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.53%
Min EPS beat(2)2.5%
Max EPS beat(2)40.56%
EPS beat(4)3
Avg EPS beat(4)17.85%
Min EPS beat(4)-4.7%
Max EPS beat(4)40.56%
EPS beat(8)6
Avg EPS beat(8)12.29%
EPS beat(12)7
Avg EPS beat(12)3.14%
EPS beat(16)8
Avg EPS beat(16)1.83%
Revenue beat(2)1
Avg Revenue beat(2)390.2%
Min Revenue beat(2)-100%
Max Revenue beat(2)880.39%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.77%
PT rev (3m)-5.77%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 60.94
P/FCF N/A
P/OCF N/A
P/B 0.42
P/tB 0.42
EV/EBITDA N/A
EPS(TTM)-5.99
EYN/A
EPS(NY)-4.77
Fwd EYN/A
FCF(TTM)-4.14
FCFYN/A
OCF(TTM)-4.11
OCFYN/A
SpS0.05
BVpS6.93
TBVpS6.93
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.15%
ROE -65.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-50.31%
ROA(5y)-40.85%
ROE(3y)-90.51%
ROE(5y)-67.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 13.47%
Cap/Sales 51.9%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.82
Quick Ratio 5.82
Altman-Z -6.27
F-Score4
WACC10.33%
ROIC/WACCN/A
Cap/Depr(3y)173.63%
Cap/Depr(5y)405.87%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.61%
EPS Next Y55.91%
EPS Next 2Y26.05%
EPS Next 3Y17.78%
EPS Next 5Y10.57%
Revenue 1Y (TTM)-72.22%
Revenue growth 3YN/A
Revenue growth 5Y17.43%
Sales Q2Q%N/A
Revenue Next Year-72.73%
Revenue Next 2Y85.56%
Revenue Next 3Y-56.54%
Revenue Next 5Y35.01%
EBIT growth 1Y20.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year16.49%
EBIT Next 3Y-12.53%
EBIT Next 5Y-18.66%
FCF growth 1Y34.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.89%
OCF growth 3YN/A
OCF growth 5YN/A